Who are LA-EP2006's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Open-label rusfertide, GerEPO, EP2006, EPORON.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/la-ep2006.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

LA-EP2006 — Competitive Intelligence Brief

LA-EP2006 (LA-EP2006) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoietin receptor agonist. Area: Hematology.

phase 3 Erythropoietin receptor agonist Erythropoietin receptor (EPOR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

LA-EP2006 (LA-EP2006) — Sandoz. LA-EP2006 is a long-acting recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to and activating the erythropoietin receptor.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LA-EP2006 TARGET	LA-EP2006	Sandoz	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor (EPOR)
Open-label rusfertide	Open-label rusfertide	Protagonist Therapeutics, Inc.	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor
GerEPO	GerEPO	Ministry of Health, Malaysia	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor (EPOR)
EP2006	EP2006	Sandoz	phase 3	Erythropoietin receptor agonist (biosimilar)	Erythropoietin receptor (EPOR)
EPORON	EPORON	Dong-A ST Co., Ltd.	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoietin receptor agonist class)

Dong-A ST Co., Ltd. · 1 drug in this class
Ministry of Health, Malaysia · 1 drug in this class
Protagonist Therapeutics, Inc. · 1 drug in this class
Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LA-EP2006 — Competitive Intelligence Brief. https://druglandscape.com/ci/la-ep2006. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab